Table 1. Patient characteristics by disease status prior to allogeneic hematopoietic stem cell transplantation in NPM1-mutated patients.

Remission status prior to allogeneic HSCT	1st CR (n=31)		2nd CR (n=20)		RD (n=16)		P-value
	No.	%	No.	%	No.	%
Median age (at time of SCT; years)	57.1		48.0		57.0
Range	21.0–70.8		29.2–70.1		43.3–63.4		0.13
Gender
Male	13	41.9	14	70	7	43.8	0.13
Female	18	58.1	6	30	9	56.2
Type of AML
de novo	26	83.9	19	95	14	87.5	0.51
secondary	2	6.5	1	5	2	12.5
therapy-related	3	9.7	-	-	-	-
Hemoglobin, g/dl
Median	9.6		8.7		10.4		0.22
Range	6.2–12.2		4.6–13.5		5.8–12.5
No. missing	-		-		-
WBC, x109/l
Median	52.3		46.2		28.3		0.77
Range	1.4–348.5		4.0–160.4		2.1–290
No. missing	-		-		-
Platelet count, x109/l
Median	77		83		103.5		0.63
Range	4–369		28–379		23–242
No. missing	-		-		-
LDH value, U/l
Median	540		539		446.5		0.67
Range	144–2741		128–2083		139–2573
No. missing	-		1		-
Percentage of BM blasts
Median	80		76		80		0.82
Range	25–100		27–95		47–90
No. missing	-		-		-
Cytogenetic risk categorya
intermediate	29	93.5	20	100	13	92.9	0.42
high	2	6.5	-	-	1	7.1
No. missing	-		-		2
FLT3-ITD mutated	13	41.9	6	30	9	56.2	0.29
No. missing	-		-		-
Donor type
MUD	18	58.1	14	70	13	81.2	0.10
MRD	13	41.9	4	20	3	18.8
Haplo	-		2	10	-

Abbreviations: AML, acute myeloid leukemia; BM, bone marrow; CR, complete remission; HSCT, hematopoietic stem cell transplantation; ITD, internal tandem duplication; LDH, lactate dehydrogenase; RD, refractory disease; WBC, white blood count.

^aAccording to reference.²⁸

^aPercentages may not add to 100 because of rounding.